



201 Technology Drive • Irvine • California • 92618
Telephone: (949) 450-5400
Facsimile: (949) 450-5300
Email: IR@endocare.com
Website: www.endocare.com

FOR RELEASE on August 8, 2008 at 6:00 am (EDT)

Investor Contact:

Matt Clawson
Allen & Caron, Inc.
(949) 474-4300
matt@allencaron.com
www.allencaron.com

Media Contact:

Len Hall
Allen & Caron, Inc.
(949) 474-4300
len@allencaron.com
www.allencaron.com

For Additional Information:

Craig T. Davenport, CEO
Michael R. Rodriguez, CFO
Endocare, Inc.
(949) 450-5400
www.endocare.com

ENDOCARE TO PRESENT AT 28th ANNUAL CANACCORD
ADAMS GLOBAL GROWTH CONFERENCE

IRVINE, CA (August 8, 2008) . . . Endocare, Inc. (NASDAQ: ENDO), an innovative medical device company focused on the development of minimally invasive technologies for tissue and tumor ablation, today announced that it is scheduled to make an investor presentation at the 28th Annual Canaccord Adams Global Growth Conference at 1:00 p.m. ET on Wednesday, August 13, 2008. The conference is being held at the InterContinental Boston hotel August 12-14.

A live webcast of the Company's presentation at the conference will be available via a link provided at <http://ir.endocare.com/events.cfm>. An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days. Web participants are encouraged to go to the Company's website (<http://ir.endocare.com/events.cfm>).

About Endocare

Endocare, Inc.—www.endocare.com— is an innovative medical device company providing minimally invasive technologies for tissue and tumor ablation. Endocare has initially concentrated on developing technologies for the treatment of prostate cancer and believes that its proprietary technologies have broad applications across a number of markets, including the ablation of tumors in the kidney, lung and liver and palliative intervention (treatment of pain associated with metastases).

###